Cripix Tablet 0.5 mg (Varenicline Salicylate)

Adult dosage

Patients should set a quit date and start taking this medication 1 week before that date. Alternatively, they may start quitting between days 8 and 35 after starting this medication. This medication should be taken after meals with plenty of water. The recommended dosage is as follows: after dose titration over 1 week, take 1 mg twice daily. Days 1–3: 0.5 mg once daily Days 4–7: 0.5 mg twice daily Day 8 until the end of treatment: 1 mg twice daily For patients who cannot tolerate the adverse reactions to this medication, the dose may be reduced temporarily or on an ongoing basis. The treatment period is 12 weeks. For patients who successfully quit smoking after the initial 12 weeks of treatment, an additional 12 weeks of treatment with this medication is recommended to increase the likelihood of long-term abstinence. For patients who cannot or do not wish to stop smoking abruptly, gradual smoking cessation while taking this medication should be considered. Smoking should be reduced by 50% from the level before treatment within the first 4 weeks after starting this medication, and by an additional 50% within the following 4 weeks. Smoking should continue to be reduced so that complete cessation is achieved by week 12. Continue this medication for an additional 12 weeks, for a total treatment period of 24 weeks. Patients who fail to quit smoking after the initial 12 weeks of treatment or resume smoking after treatment should review the reasons for failure and try again. However, there are no data demonstrating the efficacy of an additional 12 weeks of treatment in patients who fail to quit during the initial 12 weeks of treatment or resume smoking after treatment. No dose adjustment is necessary in patients with mild (estimated creatinine clearance > 50 ml/min and ≤ 80 ml/min) to moderate (estimated creatinine clearance ≥ 30 ml/min and ≤ 50 ml/min) renal impairment. In patients with severe renal impairment (estimated creatinine clearance < 30 ml/min), the recommended starting dose of varenicline is 0.5 mg once daily. If needed, the maximum dose is 0.5 mg twice daily. In patients with end-stage renal disease receiving hemodialysis, if well tolerated, a maximum dose of 0.5 mg once daily may be administered. No dose adjustment is necessary in patients with hepatic impairment. Because renal function is more likely to be reduced in elderly patients, care should be taken when selecting the dose, and monitoring renal function may be useful.

Children's dosage

Patients under 18 years of age: Use is not recommended.

This medication is used to assist in smoking cessation. However, during the use of this medication, serious mental health issues such as depression, suicidal thoughts, or suicidal behaviors may arise. All patients taking this medication should closely monitor their mental health status and must inform their doctor if they have a history of psychiatric disorders. If there are any symptoms of anxiety, restlessness, depression, unusual behavior, or changes in thinking, the patient should stop taking the medication immediately and consult a physician. Women who are pregnant or breastfeeding should use this medication cautiously and decide on its use based on necessity. Common side effects such as nausea, headache, insomnia, and abnormal dreams may occur, so caution is needed. This medication may require dose adjustments in patients with renal impairment or the elderly. Caution should also be exercised when performing potentially dangerous activities such as driving or operating machinery, as this medication might cause drowsiness or decreased concentration. Additionally, alcohol intake may lead to unusual and aggressive behaviors; thus, it is advised to avoid or minimize alcohol consumption. If any severe allergic reactions occur, such as hypersensitivity, severe skin rashes, or angioedema, the medication should be discontinued immediately, and the healthcare provider should be informed. Patients with cardiovascular diseases may experience heart-related issues due to this medication, so they should consult their physician immediately if symptoms appear. Finally, this medication is not recommended for pediatric patients under 18 years old.

• Suicidal ideation
• suicidal behavior
• suicide
• changes in behavior or thoughts
• depression
• mania
• mood changes
• psychosis
• aggressive behavior
• hallucinations

This medication should be stored in a tightly sealed container to protect it from air and moisture. It is important to maintain the storage temperature between 1 degree and 30 degrees Celsius to preserve the efficacy of the medication.

Appearance

White or grayish-white, biconvex, rectangular film-coated tablet

Package unit

11 tablets (11 tablets/BlisterX1)